- Case report
- Open Access
- Open Peer Review
This article has Open Peer Review reports available.
Severe hypercalcaemia and lymphoma in an HTLV-1 positive Jamaican woman: a case report
© Lyell et al; licensee BioMed Central Ltd. 2007
Received: 26 April 2007
Accepted: 25 July 2007
Published: 25 July 2007
Human T cell lymphotrophic virus type-1 infection is endemic in the Afro-Caribbean community in Britain, with carriage rates of about 3%. Although there is a long latency, carriers have a 1–5% chance of developing adult T cell leukaemia/lymphoma, a condition frequently complicated by marked and refractory hypercalcaemia, and with a poor prognosis. We present the case of an elderly Jamaican woman with severe hypercalcaemia and a raised PTHrP who was found to have lymphoma and was positive for HTLV-1.
An 81-year-old Jamaican woman, who had lived in the UK for many years, presented with a four week history of progressive malaise, anorexia, weakness, nausea, vomiting, drowsiness and confusion. Her only past history was of longstanding falls and dizziness. She had been taking Calcium/vitamin D tablets and prochlorperazine.
Emergency management of hypercalcaemia including hydration, loop diuretics and iv pamidronate led to initial improvement in her serum calcium level and conscious level.
Her calcium level, which had initially responded to therapy, rose rapidly again to 4.41 mmol/l. In consultation with the haematologists she was given high dose steroids, but she continued to deteriorate, with a high fever. A decision was reached, with her family, to provide palliative care only and she died shortly afterwards.
In view of the co-existence of lymphoma and hypercalcaemia, with elevated PTHrP, in this woman of Jamaican origin, Human T cell lymphotrophic virus type-1 (HTLV-1) serology was sought, and was positive, giving a presumptive diagnosis of HTLV-1-induced acute adult T cell leukaemia/lymphoma (ATLL).
ATLL is an aggressive malignancy that is aetiologically linked with the infection caused by HTLV-1. HTLV-1 infection is endemic in Japan, the Caribbean and parts of Africa . Transmission is from lymphocyte to lymphocyte in breast milk, semen or blood transfusion. Prevalence rises with age and is approximately 3% in British Jamaicans. Hence there are potentially 22, 000 infected people in the UK, predominantly older Afro-Carribeans. 1–5% of carriers develop ATLL, with a latency of 10–30 years[3, 4].
The virus belongs to the oncovirus subfamily of retroviruses and can immortalise human lymphocytes, specifically CD4 positive T lymphocytes in ATLL. Acute ATLL is invariably fatal, with a mean survival of 6 months. Prognosis is worse where there is poor performance status, age over 40, an elevated serum calcium, high level of LDH, and a higher tumour bulk.
In about 70% of cases, severe and refractory hypercalcaemia complicates acute ATLL and is one of the main causes of early death (by contrast, fewer than 4% of Hodgkin's Disease and NHL cases are associated with hypercalcaemia)[2, 5]. PTHrP, which was elevated in our patient, plays a key role in the humoral hypercalcaemia of malignancy. The peptide binds to the PTH receptor and increases both calcium levels (through bony resorption and calcium reabsorption in the kidney) and the production of pro-inflammotory cytokines, stimulating IL-6 from osteoblasts and IL-8 and TNF-a from non-bony tissue such as normal immune cells. High levels of inflammatory cytokines also potentiate the hypercalcaemic effect of PTHrP, and stimulate further PTHrP production. We were able to demonstrate raised PTHrP levels in our patient with ATLL and hypercalcaemia. ATLL patients also often express receptor activator of NF-kB ligand (RANKL), which cooperates with macrophage colony-stimulating-factor to stimulate haematopoietic precursors into osteoclasts. This effect, and the high levels of PTHrP, give rise to widespread bony resorption [2, 7] and our patient's bone scan is consistent with this.
PTHrP levels are not affected by bisphosphonate therapy and the management of the refractory hypercalcaemia of ATLL is limited. However, there are case reports of the successful use of somatostatin analogues in reducing PTHrP and calcium levels in other tumours[9, 10]. Recently, a monoclonal antibody against PTHrP has been shown to block PTHrP function and reduce calcium levels in mouse models of hypercalcaemia.
Abnormal liver function, as in our patient's case, is frequent in ATLL and results from malignant liver infiltration, though in NHL liver function is rarely affected.
Those affected by ATLL also display a degree of immunodeficiency, with impairments in T-cell function allowing for opportunistic protozoal and fungal infections. HTLV-1 carriers have high rates of Strongyloides stercoralis infection. In ATLL this gut pathogen is often associated with hyperinfection and fatal gram-negative bacteraemia, although in our patient there was no evidence of this.
Current chemotherapeutic regimens fail to alter the survival rates in ATLL, despite often inducing an initial remission. There are however reports of response to antiretroviral therapies, and of some successes in allogenic haematopoietic stem cell transplantation. Monoclonal antibodies against ATLL cells are also being developed[2, 3].
This case describes the presentation and clinical course of lymphoma in a woman from a population where HTLV-1 infection is endemic. The specific abnormalities associated with our patient's lymphoma, particularly the hypercalcaemia, raised PTHrP and abnormal liver function are all typical of ATLL associated with HTLV-1 and we were able to confirm posthumously that she was sero-positive for HTLV-1 infection.
Earlier identification of the aetiology is unlikely to have changed the outcome in this case, but the combination of lymphoma with hypercalcaemia in patients from endemic areas should alert physicians to the possibility of this diagnosis.
Hypercalcaemia is a common medical problem with a large number of potential causes, but is rarely associated with lymphoma.
Adult T cell leukaemia/lymphoma (ATLL) is frequently complicated by refractory hypercalcaemia largely due to raised PTHrP.
ATLL is rare, but much commoner in populations where HTLV-1 is endemic (in Britain, chiefly the Afro-Caribbean community).
Written consent was obtained from the patient's family for permission to publish this report. We are grateful to Professor Robert Heydermann and Dr Paul McCoubrie for their comments on the manuscript.
Consent to publication was sought and obtained from the deceased patients family.
- Peter SA, Cervantes JF: Hypercalcaemia associated with adult T-cell leukaemia/lymphoma (ATL). J Natl Med Assoc. 1995, 87: 746-8.PubMedPubMed CentralGoogle Scholar
- Matsuoka M, Jeang KT: Human T-cell leukemia virus type I at age 25: a progress report. Cancer Res. 2005, 65: 4467-70. 10.1158/0008-5472.CAN-05-0559.View ArticlePubMedGoogle Scholar
- Nicot C: Current views in HTLV-I-associated adult T-cell leukemia/lymphoma. Am J Hematol. 2005, 78: 232-9. 10.1002/ajh.20307.View ArticlePubMedGoogle Scholar
- Tosswill JHC, Taylor GP, Tedder RS, Mortimer PP: HTLV-I/II associated disease in England and Wales, 1993–7: retrospective review of serology requests. BMJ. 2000, 320: 611-612. 10.1136/bmj.320.7235.611.View ArticlePubMedPubMed CentralGoogle Scholar
- Hagler K, Lynch J: Paraneoplastic manifestations of lymphoma. Clin Lymphoma. 2004, 5: 29-36.View ArticlePubMedGoogle Scholar
- Takahashi S, Hakuta1 M, Aiba K, Ito Y, Horikoshi N, Miura1 M, Hatake K, Ogata E: Elevation of circulating plasma cytokines in cancer patients with high plasma parathyroid hormone-related protein levels. Endocrine-Related Cancer. 2003, 10: 403-407. 10.1677/erc.0.0100403.View ArticlePubMedGoogle Scholar
- Clines G, Guise T: Hypercalcaemia of malignancy and basic research on mechanisms responsible for osteolytic and osteoblastic metastasis to bone. Endocrine-Related Cancer. 2005, 12: 549-583. 10.1677/erc.1.00543.View ArticlePubMedGoogle Scholar
- Rizzoli R, Thiébaud D, Bundred N, Pecherstorfer M, Herrmann Z, Huss HJ, Rückert F, Manegold C, Tubiana-Hulin M, Steinhauer EU, Degardin M, Thürlimann B, Clemens MR, Eghbali H, Body JJ: Serum Parathyroid Hormone-Related Protein Levels and Response to Bisphosphonate Treatment in Hypercalcemia of Malignancy. J Clin Endocrinol Metab. 1999, 84 (10): 3545-3550. 10.1210/jc.84.10.3545.View ArticlePubMedGoogle Scholar
- Anthony LB, May ME, Oates JA: Case report: lanreotide in the management of hypercalcemia of malignancy. Am J Med Sci. 1995, 309 (6): 312-4.View ArticlePubMedGoogle Scholar
- Jones RA, O'Grady J, Chambers S, Heaton N, Ramage JK, Aylwin SJB: Octreotide in the treatment of PTHrP related hypercalcaemia in neuroendocrine tumours: a case report and literature review. Presented at Society for Endocrinology Annual Meeting 2005, London, UK. 2005, Endocrine Abstracts, 10: 42-Google Scholar
- Onuma E, Sato K, Saito H, Tsunenari T, Ishii K, Esaki K, Yabuta N, Wakahara Y, Yamada-Okabe H, Ogata E: Generation of a humanized monoclonal antibody against human parathyroid hormone-related protein and its efficacy against humoral hypercalcemia of malignancy. Anticancer Res. 2004, 24: 2665-74.PubMedGoogle Scholar
- Carvalho EM, Da Fonseca Porto A: Epidemiological and clinical interaction between HTLV-1 and Strongyloides stercoralis. Parasite Immuno. 2004, 26: 487-97. 10.1111/j.0141-9838.2004.00726.x.View ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.